SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Byers Robert M.)
 

Sökning: WFRF:(Byers Robert M.) > Clinical insights i...

  • Megyesfalvi, ZsoltNational Korányi Institute for Tuberculosis and Pulmonology, Hungary,National Institute of Oncology, Budapest,Medical University of Vienna (författare)

Clinical insights into small cell lung cancer : Tumor heterogeneity, diagnosis, therapy, and future directions

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2023

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:ab89be12-9718-4381-a3b3-1fc2d055fa46
  • https://lup.lub.lu.se/record/ab89be12-9718-4381-a3b3-1fc2d055fa46URI
  • https://doi.org/10.3322/caac.21785DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:for swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53 and RB1, and a high mutation burden. Because of early metastasis, only a small fraction of patients are amenable to curative-intent lung resection, and these individuals require adjuvant platinum-etoposide chemotherapy. Therefore, the vast majority of patients are currently being treated with chemoradiation with or without immunotherapy. In patients with disease confined to the chest, standard therapy includes thoracic radiotherapy and concurrent platinum-etoposide chemotherapy. Patients with metastatic (extensive-stage) disease are treated with a combination of platinum-etoposide chemotherapy plus immunotherapy with an anti-programmed death-ligand 1 monoclonal antibody. Although SCLC is initially very responsive to platinum-based chemotherapy, these responses are transient because of the development of drug resistance. In recent years, the authors have witnessed an accelerating pace of biologic insights into the disease, leading to the redefinition of the SCLC classification scheme. This emerging knowledge of SCLC molecular subtypes has the potential to define unique therapeutic vulnerabilities. Synthesizing these new discoveries with the current knowledge of SCLC biology and clinical management may lead to unprecedented advances in SCLC patient care. Here, the authors present an overview of multimodal clinical approaches in SCLC, with a special focus on illuminating how recent advancements in SCLC research could accelerate clinical development.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gay, Carl M.University of Texas (författare)
  • Popper, HelmutMedical University of Graz (författare)
  • Pirker, RobertMedical University of Vienna (författare)
  • Ostoros, GyulaNational Korányi Institute for Tuberculosis and Pulmonology, Hungary (författare)
  • Heeke, SimonUniversity of Texas (författare)
  • Lang, ChristianMedical University of Vienna (författare)
  • Hoetzenecker, KonradMedical University of Vienna (författare)
  • Schwendenwein, AnnaMedical University of Vienna (författare)
  • Boettiger, KristiinaMedical University of Vienna (författare)
  • Bunn, Paul A.University of Colorado School of Medicine (författare)
  • Renyi-Vamos, FerencNational Institute of Oncology, Budapest,National Korányi Institute for Tuberculosis and Pulmonology, Hungary (författare)
  • Schelch, KarinMedical University of Vienna (författare)
  • Prosch, HelmutVienna General Hospital / University Hospital Vienna (författare)
  • Byers, Lauren A.University of Texas (författare)
  • Hirsch, Fred R.University of Colorado,Icahn School of Medicine at Mount Sinai (författare)
  • Dome, BalazsLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,Medical University of Vienna,Semmelweis University,National Korányi Institute for Tuberculosis and Pulmonology, Hungary(Swepub:lu)ba1464do (författare)
  • National Korányi Institute for Tuberculosis and Pulmonology, HungaryNational Institute of Oncology, Budapest (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:CA: a cancer journal for clinicians73:6, s. 620-6520007-9235

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy